Corcept Therapeutics Inc
CORT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001088856
In the last 90 days, Corcept Therapeutics Inc insiders filed 0 open-market purchases and 17 sales; 425 institutions reported holding it in 13F filings for Q2 2026, worth $7.15B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:10 AM ET
Revenue flow, Q3 FY2026
Where the revenue went in Q3 FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one quarter, newest first.
| Line item | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 3, 2026 | Jul 29, 2026 | Apr 30, 2026 | Feb 24, 2026 | Nov 4, 2025 | Jul 31, 2025 | May 5, 2025 | Feb 26, 2025 |
| Revenue | $340.5M | $256.1M | $164.9M | $202.1M† | $207.6M | $194.4M | $157.2M | $181.9M† |
| Cost of revenue | $4.61M | $4.06M | $2.88M | $2.54M† | $4.60M | $3.43M | $2.40M | $2.96M† |
| Research and development | $56.7M | $53.9M | $66.3M | $64.9M† | $68.8M | $60.5M | $60.7M | $70.3M† |
| Selling, general and administrative | $164.4M | $156.9M | $145.4M | $130.2M† | $124.0M | $103.9M | $90.7M | $83.4M† |
| Operating income | $114.7M | $41.3M | -$49.6M | $4.49M† | $10.2M | $26.7M | $3.42M | $25.3M† |
| Income tax | -$6.47M | $2.94M | -$13.0M | -$14.4M† | -$4.42M | -$3.46M | -$10.9M | $1.21M† |
| Net income | $126.8M | $43.0M | -$31.8M | $24.3M† | $19.7M | $35.1M | $20.5M | $30.7M† |
| EPS, basic | $1.17 | $0.40 | $-0.30 | – | $0.19 | $0.33 | $0.19 | – |
| EPS, diluted | $1.01 | $0.36 | $-0.30 | – | $0.16 | $0.29 | $0.17 | – |
| Weighted shares, basic | 106.6M | 105.4M | 104.4M | – | 103.5M | 104.1M | 104.1M | – |
| Weighted shares, diluted | 123.2M | 118.4M | 104.4M | – | 119.4M | 120.5M | 119.8M | – |
| Margins and growth | ||||||||
| Operating margin | 33.7% | 16.1% | -30.1% | 2.2% | 4.9% | 13.7% | 2.2% | 13.9% |
| Net margin | 37.2% | 16.8% | -19.3% | 12.0% | 9.5% | 18.1% | 13.1% | 16.9% |
| Revenue growth, year over year | +64.0% | +31.7% | +4.9% | +11.1% | +13.7% | +18.7% | +7.1% | +34.3% |
| Net income growth, year over year | +544.6% | +22.3% | −254.6% | −21.0% | −58.3% | −1.0% | −26.0% | −1.9% |
Balance sheet
Each column is one quarter, newest first.
| Line item | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 3, 2026 | Jul 29, 2026 | Apr 30, 2026 | Feb 24, 2026 | Nov 4, 2025 | Jul 31, 2025 | May 5, 2025 | Feb 26, 2025 |
| Cash and equivalents | $98.7M | $111.0M | $108.7M | $120.5M | $125.1M | $102.7M | $89.8M | $127.7M |
| Short-term investments | $272.0M | $197.2M | $229.4M | $251.7M | $296.5M | $239.5M | $232.9M | $255.7M |
| Accounts receivable | $111.1M | $76.9M | $39.1M | $59.8M | $69.6M | $64.6M | $61.8M | $54.0M |
| Inventory | $11.9M | $13.2M | $12.9M | $12.9M | $12.3M | $12.3M | $14.4M | $12.4M |
| Total current assets | $533.9M | $439.7M | $426.0M | $485.5M | $541.1M | $443.1M | $438.5M | $471.6M |
| Property, plant and equipment | $4.94M | $5.13M | $3.17M | $1.89M | $2.09M | $2.35M | $2.54M | $2.69M |
| Total assets | $1.03B | $888.7M | $814.9M | $836.7M | $823.6M | $801.7M | $846.5M | $840.6M |
| Accounts payable | $21.9M | $14.9M | $33.3M | $40.4M | $34.4M | $23.5M | $27.9M | $15.4M |
| Total current liabilities | $177.7M | $153.8M | $149.2M | $166.1M | $172.3M | $144.7M | $143.1M | $140.8M |
| Total liabilities | $200.3M | $182.9M | $176.9M | $188.8M | $191.7M | $165.9M | $163.2M | $161.0M |
| Shareholders' equity | $833.7M | $705.8M | $638.0M | $647.8M | $631.9M | $635.8M | $683.3M | $679.6M |
Cash flow statement
Each column is one quarter, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | Q3 FY2026† | Q2 FY2026† | Q1 FY2026 | Q4 FY2025† | Q3 FY2025† | Q2 FY2025† | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 3, 2026 | Jul 29, 2026 | Apr 30, 2026 | Feb 24, 2026 | Nov 4, 2025 | Jul 31, 2025 | May 5, 2025 | Feb 26, 2025 |
| Operating cash flow | $142.9M† | $33.5M† | -$16.8M | $38.4M† | $54.5M† | $43.9M† | $5.13M | $59.3M† |
| Capital expenditures | $709.0K† | $2.53M† | $201.0K | $50.0K† | $0† | $57.0K† | $104.0K | $121.0K† |
| Free cash flow | $142.2M | $31.0M | -$17.0M | $38.4M | $54.5M | $43.9M | $5.02M | $59.2M |
| Depreciation and amortization | $1.03M† | $863.0K† | $598.0K | $289.0K† | $289.0K† | $286.0K† | $285.0K | $281.0K† |
| Stock-based compensation | $29.4M† | $29.4M† | $23.0M | $20.8M† | $22.9M† | $19.0M† | $21.8M | $16.8M† |
| Share buybacks | $5.75M† | $0† | $0 | $0† | $42.5M† | $103.0M† | $27.4M | $0† |
| Investing cash flow | -$132.0M† | -$29.2M† | $4.54M | -$11.8M† | $14.6M† | $70.1M† | -$3.17M | -$64.4M† |
| Financing cash flow | -$23.9M† | -$2.04M† | $760.0K | -$31.2M† | -$46.4M† | -$102.9M† | -$39.8M | -$4.56M† |
| Net change in cash | -$12.9M† | $2.30M† | -$11.8M | -$4.64M† | $22.4M† | $12.9M† | -$37.8M | -$9.62M† |
| Ratio | ||||||||
| Stock-based compensation, % of revenue | 8.6% | 11.5% | 14.0% | 10.3% | 11.0% | 9.8% | 13.9% | 9.2% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 22, 2026 | 109.4M | +4.0% | SEC |
| Jul 22, 2026 | 108.1M | +2.6% | SEC |
| Apr 23, 2026 | 107.4M | +1.2% | SEC |
| Feb 17, 2026 | 106.4M | +0.8% | SEC |
| Oct 23, 2025 | 105.2M | +0.4% | SEC |
| Jul 24, 2025 | 105.4M | +0.8% | SEC |
| Apr 28, 2025 | 106.0M | +1.9% | SEC |
| Feb 18, 2025 | 105.5M | +1.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- Values marked † are derived: Q4 is the full year minus the first three quarters, single-quarter cash flows are year-to-date figures minus the previous year-to-date figures, and the Q4 balance sheet is the year-end balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.